Correction to: Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects

Affiliations

• ¹ Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesu Children's Hospital, IRCCS, Via S. Paolo, 15, 00146, Rome, Italy.
• ² Unit of Oncogenomic and Epigenetic, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
• ³ Experimental Imaging Center, IRCCS San Raffaele Scientific Institute, 20132, Milan, Italy.
• ⁴ Core Facilities, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ⁵ Department of Paediatric Haematology/Oncology and Cellular and Gene Therapy, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ⁶ Unit of Human Microbiome, Multimodal Laboratory Medicine Research Area, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ⁷ Unit of Microbiomics, Microbiology and Immunological Diagnostics, Department of Diagnostics and Laboratory Medicine Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ⁸ International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
• ⁹ Department of Translational Stem Cell Biology, Research Institute of the Medical University of Varna, 9002, Varna, Bulgaria.
• ¹⁰ Department of Life, Health and Environmental Sciences MESVA, University of L'Aquila, L'Aquila, Italy.
• ¹¹ Francesco Balsano Foundation, Rome, Italy.
• ¹² Research Unit of Diagnostical and Management Innovations, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ¹³ Genetics and Rare Diseases Research Division, Bambino Gesu Children's Hospital, IRCCS, Rome, Italy.
• ¹⁴ Unit of Molecular Genetics of Complex Phenotypes, Bambino Gesu Children's Hospital, IRCCS, Via S. Paolo, 15, 00146, Rome, Italy. anna.alisi@opbg.net.